Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Income Statement
Quarterly Data

Moderna Inc., consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net product sales 1,757 293 1,828 4,859 3,120 4,531 5,925 6,935 4,810 4,197 1,733 200
Cost of sales (2,241) (731) (792) (1,918) (1,100) (1,381) (1,017) (952) (722) (750) (193) (8)
Gross profit (loss) (484) (438) 1,036 2,941 2,020 3,150 4,908 5,983 4,088 3,447 1,540 192
Other revenue 74 51 34 225 244 218 141 276 159 157 204 371 158 66 8 14 17 13 16
Research and development (1,160) (1,148) (1,131) (1,211) (820) (710) (554) (648) (521) (421) (401) (759) (344) (152) (115) (118) (120) (128) (130)
Selling, general and administrative (442) (332) (305) (375) (278) (211) (268) (201) (168) (121) (77) (79) (49) (37) (24) (26) (28) (28) (27)
Income (loss) from operations (2,012) (1,867) (366) 1,580 1,166 2,447 4,227 5,410 3,558 3,062 1,266 (275) (235) (122) (131) (130) (131) (144) (142)
Interest income 105 104 109 87 58 40 15 7 4 3 4 4 6 7 8 8 9 10 11
Other income (expense), net (51) 14 (48) (12) (7) (13) (13) (7) (10) (2) (10) (3) (2) (1) (2) (2) (2) (2)
Income (loss) before income taxes (1,958) (1,749) (305) 1,655 1,217 2,474 4,229 5,410 3,552 3,063 1,260 (271) (233) (117) (124) (123) (123) (135) (133)
(Provision for) benefit from income taxes (1,672) 369 384 (190) (174) (277) (572) (542) (219) (283) (39) (1) (1)
Net Income (loss) (3,630) (1,380) 79 1,465 1,043 2,197 3,657 4,868 3,333 2,780 1,221 (272) (234) (117) (124) (123) (123) (135) (133)

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Net product sales Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Moderna Inc. net product sales decreased from Q1 2023 to Q2 2023 but then increased from Q2 2023 to Q3 2023 not reaching Q1 2023 level.
Income (loss) from operations The net result for the period of deducting operating expenses from operating revenues. Moderna Inc. income (loss) from operations decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Income (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Moderna Inc. income (loss) before income taxes decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Net Income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Moderna Inc. net Income (loss) decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.